Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced \ o1/o7/96 \ \ Origin: Appendix \ 5 \ \ Amended \ o1/o7/98, \ o1/o9/99, \ o1/o7/o0, \ 30/o9/o1, \ 11/o3/o2, \ o1/o1/o3, \ 24/10/o5, \ o1/o8/12, \ o4/o3/13$

Name of entity ADS MEMORY I MITTED				
4DS M	4DS MEMORY LIMITED			
ABN 43 145	590 110			
We (th	information.			
Part 1 - All issues You must complete the relevant sections (attach sheets if there is not enough space).				
1	*Class of *securities issued or to be issued	Fully paid ordinary shares		
2	Number of ⁺ securities issued or to be issued (if known) or maximum number which may be issued	3,000,000		
3	Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	Fully paid ordinary shares		

04/03/2013 Appendix 3B Page 1

⁺ See chapter 19 for defined terms.

Yes - the shares issued rank equally with existing Do the +securities rank equally listed fully paid ordinary shares. in all respects from the +issue date with an existing +class of quoted +securities? If the additional +securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution interest payment Issue price or consideration \$0.049 per share 5 6 Purpose of the issue Exercise of unlisted 18 October 2019 options (If issued as consideration for the acquisition of assets, clearly identify those assets) 6a Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b - 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i 6b The date the security holder 31 October 2017 resolution under rule 7.1A was passed 6c Nil Number of +securities issued without security holder approval under rule 7.1 6d Nil Number of +securities issued with security holder approval under rule 7.1A

6e	Number of +securities issued
	with security holder approval
	under rule 7.3, or another
	specific security holder approval
	(specify date of meeting)

Nil

6f Number of +securities issued under an exception in rule 7.2

3,000,000 fully paid ordinary shares under exception 4

6g If +securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation.

N/A

6h If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements N/A

6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements

7.1 141,822,181 7.1A 94,548,121

7 +Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

18 January 2018

8 Number and *class of all *securities quoted on ASX (including the *securities in section 2 if applicable)

	Number	⁺ Class
1	945,481,210	Fully paid ordinary shares
1		

9 Number and *class of all *securities not quoted on ASX (*including* the *securities in section 2 if applicable)

Number	+Class
10,833,334	Options @ \$0.024 expiring on
	10/5/2018
3,000,000	Options @ \$0.042 expiring on
	25/6/2018

04/03/2013 Appendix 3B Page 3

⁺ See chapter 19 for defined terms.

	36,458,333	Options @ \$0.02 expiring on 30/6/2020.
	32,500,000	Options @ \$0.05 expiring on 30/6/2020.
	5,000,000	Options @ \$0.05 expiring on 31/12/2019.
	28,275,000	Options @ \$0.042 expiring on 27/10/2022.
	5,000,000	Options at \$0.07 expiring on 30/6/2020
Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	N/A	
2 - Pro rata issue		
Is security holder approval required?		
Is the issue renounceable or non-renounceable?		
Ratio in which the *securities will be offered		
⁺ Class of ⁺ securities to which the offer relates		
⁺ Record date to determine entitlements		
Will holdings on different registers (or subregisters) be aggregated for calculating		

10

11

12

13

14

15

16

17

Part 2 - Pro rata issue

entitlements?

in relation to fractions

Policy for deciding entitlements

18	Names of countries in which the entity has security holders who will not be sent new offer documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	
20	Names of any underwriters	
21	Amount of any underwriting fee or commission	
22	Names of any brokers to the issue	
23	Fee or commission payable to the broker to the issue	
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	
25	If the issue is contingent on security holders' approval, the date of the meeting	
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	
28	Date rights trading will begin (if applicable)	
29	Date rights trading will end (if applicable)	

o4/o3/2013 Appendix 3B Page 5

⁺ See chapter 19 for defined terms.

30	How do security holders sell their entitlements in full through a broker?		
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?		
32	How do security holders dispose of their entitlements (except by sale through a broker)?		
33	⁺ Issue date		
	- Quotation of securities only complete this section if you are applying for quotation of securities		
34	Type of *securities (tick one)		
(a)	X *Securities described in Part 1		
(b)	All other ⁺ securities Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities		
Entitie	s that have ticked box 34(a)		
Additional securities forming a new class of securities			
Tick to	indicate you are providing the information or nts		
35	If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders		
36	If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories 1 - 1,000		
	1,001 - 5,000		
	5,001 - 10,000 10,001 - 100,000		
	100,001 and over		
37	A copy of any trust deed for the additional *securities		

Entities that have ticked box 34(b)

38	Number of *securities for which *quotation is sought	N/A	
39	⁺ Class of ⁺ securities for which quotation is sought	N/A	
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	N/A	
	If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another +security, clearly identify that other +security)	N/A	
42	Number and +class of all +securities quoted on ASX (including the +securities in clause 38)	Number N/A	+Class

Quotation agreement

[†]Quotation of our additional *securities is in ASX's absolute discretion. ASX may quote the *securities on any conditions it decides.

o4/o3/2013 Appendix 3B Page 7

⁺ See chapter 19 for defined terms.

- 2 We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the ⁺securities to be quoted under section 1019B of the Corporations Act at the time that we request that the ⁺securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date 18 January 2018

(Company Secretary)

Print name: Peter Webse

== == == ==

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
<i>Insert</i> number of fully paid ⁺ ordinary securities on issue 12 months before the ⁺ issue date or date of agreement to issue	845,563,360	
Add the following:		
Number of fully paid ⁺ ordinary securities issued in that 12 month period under an exception in rule 7.2	18,833,334 (Comprising the issue of Shares on exercise of options)	
Number of fully paid ⁺ ordinary securities issued in that 12 month period with shareholder approval	959,516 Shares issued on 3/11/2017, which was approved by shareholders on 31 October 2017	
Number of partly paid ⁺ ordinary securities that became fully paid in that 12 month period	80,125,000 Shares issued on 10/11/2017, which was approved by shareholders on 8 January 2018.	
Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items		
Subtract the number of fully paid +ordinary securities cancelled during that 12 month period	-	
"A"	945,481,210	

⁺ See chapter 19 for defined terms.

o4/o3/2013 Appendix 3B Page 9

Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
Multiply "A" by 0.15	141,822,181	
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used		
Insert number of ⁺ equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:	-	
• Under an exception in rule 7.2		
Under rule 7.1A		
 With security holder approval under rule 7.1 or rule 7.4 		
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 		
"C"	-	
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1		
"A" x 0.15	141,822,181	
Note: number must be same as shown in Step 2		
Subtract "C"	-	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" × 0.15] – "C"	141,822,181	
	[Note: this is the remaining placement capacity under rule 7.1]	

Part 2

Rule 7.1A – Additional placen	nent capacity for eligible entities	
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A" Note: number must be same as shown in Step 1 of Part 1	945,481,210	
Step 2: Calculate 10% of "A"		
"D"	0.10 Note: this value cannot be changed	
Multiply "A" by 0.10	94,548,121	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
 Insert number of +equity securities issued or agreed to be issued in that 12 month period under rule 7.1A Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items 	-	
"E"	-	
Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10	94,548,121	
Note: number must be same as shown in Step 2		
Subtract "E"	-	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.10] – "E"	94,548,121	

⁺ See chapter 19 for defined terms.

04/03/2013 Appendix 3B Page 11